Substance / Medication

Danaparoid sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

44 trials linked to this intervention

44
Total Trials
14
Recruiting
7
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin.
Iba Toshiaki, Kidokoro Akio, Fukunaga Masaki et al. · Intensive Care Med · 2005
PMID: 15995859Observational
[A case of portal vein thrombosis complicating acute cholangitis treated successfully with danaparoid sodium].
Oku Takatomi, Kubo Yasunori, Miseki Tetsuya et al. · Nihon Shokakibyo Gakkai Zasshi · 2010
PMID: 21071899Case Report
[An operated case of retroperitoneal venous hemangioma complicated with Kasabach-Merritt syndrome which was well controlled by danaparoid sodium].
Moriguchi Aya, Iwahashi Kiyoshi, Onishi Yoshiki et al. · Nihon Shokakibyo Gakkai Zasshi · 2009
PMID: 19893297Case Report
Extracorporeal membrane oxygenation with danaparoid sodium after massive pulmonary embolism.
Bauer Christian, Vichova Zuzana, Ffrench Patrick et al. · Anesth Analg · 2008
PMID: 18349178Case Report
[Case of cardial varices rupture due to danaparoid sodium with portal venous thrombosis].
Kawaratani Hideto, Matsumura Masahiko, Tsujimoto Tatsuhiro et al. · Nihon Shokakibyo Gakkai Zasshi · 2008
PMID: 19057161Case Report
[Treatment by danaparoid sodium for portal venous thrombosis].
Shudo Ryushi, Yazaki Yasuyuki, Sugawara Kenji et al. · Nihon Shokakibyo Gakkai Zasshi · 2007
PMID: 17283415Case Report
Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin.
Antonijevic Nebojsa M, Savic Nebojsa B, Perunicic Jovan et al. · J Clin Apher · 2006
PMID: 16933276Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Danaparoid sodium (substance)
SNOMED CT
386954009
UMLS CUI
C0353453

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
44
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.